New Delhi: Drug firm Bajaj Healthcare on Tuesday announced the launch of its anti-parasitic drug 'Ivejaj', which can be used for treatment of COVID infections.
The company has received approval from India's drug regulator DCGI to manufacture and market the tablets, it said in a BSE filing.
Bajaj Healthcare said it has successfully developed the active pharmaceutical ingredient and the formulation for Ivermectin through its own in-house R&D team.
The DCGI has granted permissions to supply 'Ivejaj' in the domestic as well as overseas markets, Bajaj Healthcare said.
Shares of the company rose 2.71 per cent to Rs 603.30 apiece on BSE.
Roche's antibody cocktail gets approval
On Wednesday, Drug firm Roche India said it has received Emergency Use Authorisation (EUA) from the Central Drugs Standards Control Organisation (CDSCO) for Roche's investigational antibody cocktail used in the treatment of COVID-19.
The antibody cocktail is to be administered for the treatment of mild to moderate coronavirus disease in adults and pediatric patients (12 years of age or older, weighing at least 40 kg) who are confirmed to be infected with SARS-COV2 and who are at high risk of developing severe COVID-19 disease, the company said in a statement.
In the last 24 hours, India has added over 4.12 lakh Covid-19 infections. According to the health ministry data, this was the second time that the daily tally breached the 4-lakh mark, after nearly 4.02 lakh cases were recorded on April 30.
(With PTI Inputs)
